Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Busy triage point outside the Emergency Department at the Christian Medial College, Vellore, Tamil Nadu, India © Ms Priyanka Gautam, Christian Medical College, Vellore, India

In a study published 21 March in Clinical Infectious Diseases, the PRIORITISE study team report the development and validation of three clinical prediction models that could help identify patients presenting with moderate Covid-19 who could safely be managed in the community. Identification of patients suitable for outpatient management could help decompress and protect health systems during current and future spikes in infections, especially in locations where capacity for inpatient monitoring is limited. The models, which contain three easily ascertainable clinical parameters (age, sex, SpO2) and one biomarker (IL-6, NLR or suPAR) measurable using a point-of-care test, would be readily implementable in many LMIC settings. The study was a collaboration between MSF India and MORU, in partnership with the teams at CMC Vellore and AIIMS Patna, supported by FIND, and funded by MSF and the Wellcome Trust.

The PRIORITISE team would like to hear from groups interested in collaborating to further validate the findings. This is important before the models can be recommended for use. Ideally this would happen before another surge in infections, so partners who already have baseline clinical data and bio-banked plasma from patients with moderate Covid-19, alongside data on clinical outcomes over the next 14-28 days, are encouraged to get in touch.

Please share and, if interested, kindly contact Arjun Chandna or Sakib Burza

Read the full publication 'Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings' on the Clinical Infectious Diseases website

- Text courtesy of Arjun Chandna, on behalf of the PRIORITISE team, with thanks to Ms. Priyanka Gautam, Christian Medical College, Vellore, India for the photo.

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.